For patients with non-Hodgkin's lymphoma (NHL) undergoing blood or bone marrow transplantation (BMT), the use of autologous grafts has often been preferred to that of allogeneic stem cells because of a significantly lower incidence of non-relapse mortality. If complications associated with allo-BMT could be minimized without compromising efficacy, then it might become a preferred strategy for certain subsets of patients. In this report, we describe the toxicity and long-term efficacy of T cell-depleted allogeneic BMT using anti-CD6 monoclonal antibody and complement alone to reduce the risk of GVHD and its sequelae. Twenty-two patients, aged 18-60 years, with high (n = 10), intermediate (n = 9), or low (n = 3) grade NHL underwent HLA-identical allogeneic BMT from siblings. Patients had either relapsed after at least one remission or never achieved a full remission with chemotherapy. Twenty patients had a history of marrow involvement. Bone marrow was depleted of CD6 + T cells with T12 monoclonal antibody and complement as the sole form of GVHD prophylaxis. Stable hematopoietic engraftment occurred in all 22 patients. Four patients developed grade 2 and 1 patient grade 3 GVHD (23% grades 2-4 GVHD). Chronic GVHD has occurred in three patients. Treatment-related mortality was very low. Only one patient died while in remission. Thirteen patients are alive and free of disease with a median follow-up of 30 months. Estimated event-free and overall survivals are 54 and 59%, respectively. CD6 allogeneic marrow transplantation is associated with a low risk of transplant-related complications and may offer advantages for certain patients with recurrent NHL felt to be at high risk for relapse after autologous transplantation.
(NHL) that has recurred following standard chemotherapy. [1] [2] [3] [4] Long-term remissions and apparent cures have been attained in 30-50% of patients transplanted with chemosensitive disease. The majority of such procedures have utilized autologous hematopoietic stem cells obtained from a patient's bone marrow or peripheral blood.
Autologous stem cells have historically been preferred over allogeneic stem cells because of several factors, including greater donor availability and the absence of immunologically mediated complications such as graftversus-host disease (GVHD). However, the use of autologous stem cell products has its own potential disadvantages. Autologous marrow and peripheral blood may contain occult clonogenic tumor cells which, when reinfused, may contribute to the subsequent development of relapse post-BMT/PBSCT. In addition, while autologous stem cells may not induce GVHD, they in turn may fail to provide the antitumor activity typically associated with allogeneic marrow following transplantation for certain leukemias. Such potential graft-versus-lymphoma activity may be particularly important since relapse is the primary reason for failure following autologous transplantation for NHL. Several studies in patients with NHL have reported lower relapse rates after allogeneic BMT than after autologous transplant. [5] [6] [7] [8] [9] Lastly, in recent years, the risk of long-term complications such as myelodysplasia and secondary leukemias following autologous BMT for lymphoma has been recognized with increasing frequency. 10, 11 If the morbidity and mortality associated with allogeneic transplantation could be reduced, then it might prove a superior alternative to autologous transplant procedures in certain patients with recurrent lymphoma. Our encouraging experience with CD6 + T cell depletion as a means of GVHD prophylaxis in patients transplanted for leukemia led us to perform allogeneic BMT using this approach in patients with recurrent NHL who were either ineligible for autologous BMT at our institution or felt to be at very high risk of relapse following autologous transplant. 12, 13 In patients with leukemia, CD6 depletion has been associated with a high rate of engraftment, a low incidence of acute and chronic GVHD in the absence of immune suppressive medications for GVHD prophylaxis, and relatively low transplant-related mortality. 12, 13 We report the results of 22 patients with NHL who underwent CD6 + T cell-depleted allogeneic transplantation. Our results indicate that this strategy of employing allogeneic marrow clearly uncon-taminated by lymphoma and not exposed to prior chemotherapy may lead to a high percentage of long-term remissions without the development of significant complications due to GVHD.
Patients and methods

Patient population
Between July 1990 and June 1996, 22 patients with a diagnosis of NHL underwent allogeneic BMT at DFCI. Patients receiving allogeneic marrow had not been eligible for treatment on a B cell monoclonal antibody purged autologous BMT protocol at our institution because of high grade tumor histology (n = 10), prior autologous transplantation (n = 4), T cell immunophenotype (n = 4), greater than 10% marrow involvement with lymphoma at the time of BMT (n = 3), or concern about poor hematopoietic stem cell reserve (n = 1). Eligibility criteria included chemosensitive disease and no more than 20% bone marrow involvement with lymphoma. Treatment protocols were approved by the Human Subjects Protection Committee of DFCI. Written informed consent was obtained in all cases.
Treatment protocol
Nineteen patients received cyclophosphamide 60 mg/kg i.v. ϫ 2 on 2 consecutive days followed by total body irradiation (TBI) as ablation. TBI was administered in seven to eight equal fractions given twice daily, 5-6 h apart. All patients had been treated on a dedicated facility at a dose rate of 10 cGy/min. The dose of TBI was escalated between 1990 and 1996 for all patients at our institution. Patients received 1400 (n = 9), 1480 (n = 5) or 1560 (n = 4) cGy. Four patients who had received prior radiotherapy sufficient to preclude TBI received busulfan (16 mg/kg over 4 days) plus cyclophosphamide (60 mg/kg i.v. ϫ 2) as their ablative regimen.
Donor bone marrow was harvested on the last day of TBI administration. Marrow was depleted of CD6 + T cells by complement-mediated antibody lysis using anti-T12 monoclonal antibody as previously described.
12 T12 is a murine IgM monoclonal antibody which recognizes the CD6 antigen on T cells but does not react with thymocytes, NK cells, B cells, monocytes or myeloid precursors. 13 Three rounds of incubation with T12 and rabbit complement has been demonstrated to remove approximately 1.5-2 logs of T cells from donor marrow.
14 Marrow was infused into the patient through an indwelling central venous catheter the same day it was harvested. No patients received prophylactic immunosuppressive therapy of any type, including corticosteroids, methotrexate, or cyclosporine. Since January 1994, 14 patients received granulocyte colony-stimulating factor (G-CSF) beginning at day +1 and continuing until the absolute neutrophil count exceeded 1.0 ϫ 10 9 cells/l. All patients were treated in HEPA filtered rooms using standard reverse isolation procedures. Oral prophylactic antibiotics, either ciprofloxacin or trimethoprim-sulfamethoxazole, were administered to all patients as was prophylactic acyclovir. These were discontinued when patients developed fevers that required initiation of broad-spectrum intravenous antibiotics. All patients received single donor platelets from cytomegalovirus seronegative individuals and frozen deglycerolized red blood cells. All blood components were irradiated to prevent transfusion-related GVHD.
Patient evaluation
Data were evaluated as of 1 January 1997. Neutrophil engraftment was defined as the first of 2 consecutive days in which the absolute neutrophil count exceeded 0.5 ϫ 10 9 cells/l. Platelet engraftment was defined as the first of 7 consecutive days in which the platelet count was greater than 20 ϫ 10 9 cells/l independent of transfusion. Acute GVHD was graded according to the criteria established by Glucksberg et al. 15 Remission status was assessed by physical examinations, radiographs, computed tomography, and bone marrow evaluation at approximately 3, 6 and 12 months post-BMT and then yearly thereafter or as clinically indicated.
Statistical considerations
Event-free survival (EFS) was measured from the date of bone marrow infusion to the date of relapse, progression, or date of death in remission; patients were censored at the date on which they were last seen and reported without disease. Overall survival (OS) was measured from the date of bone marrow infusion to the date of death or date last known alive. EFS and OS are calculated by the method of Kaplan and Meier, with confidence intervals given by Greenwood's formula. 16 EFS and OS were compared according to patient characteristics using the logrank test. 17 The Wilcoxon test was used to compare time to neutrophil and platelet recovery in patients treated with and without G-CSF. 18 
Results
Patient characteristics
The characteristics of the 22 patients undergoing CD6-depleted allogeneic transplantation for NHL are listed in Table 1 . There were 14 males and eight females with a median age of 36 years (range 18-59 years). At the time of transplant, all patients had evidence of chemosensitive disease. Six patients were in complete remission and 16 were in partial remission. Prior to BMT, 12 patients had been treated with three or more combination chemotherapy regimens, nine had received two different regimens, and one patient had received one course of chemotherapy. Four patients had relapsed from a prior autologous transplant for lymphoma.
By the Working Formulation, 10 patients could be classified as having high-grade disease: lymphoblastic lymphoma (n = 3), small non-cleaved Burkitt's (n = 2), small noncleaved non-Burkitt's (n = 3), and immunoblastic (n = 2). Nine patients could be classified as having intermediate- grade disease: diffuse large cell (n = 6), mantle cell (n = 1), T cell-rich B cell (n = 1) and diffuse small cleaved cell (n = 1). Three additional patients (all with follicular lymphoma) were considered to have low-grade disease. Four patients had immunophenotypic studies suggesting T cell-derived lymphoma. The remainder had B cell disease. Twenty of 22 (91%) patients had demonstrated evidence of bone marrow involvement at some time prior to BMT, with 14 (63%) of these patients having histologic evidence of marrow disease upon admission for BMT.
Engraftment
All 22 patients achieved full hematopoietic engraftment. There were no cases of early graft rejection or late graft failure. The median time to achieve an absolute neutrophil count of 0.5 ϫ 10 9 /l was 14 days after marrow infusion (range 10-25 days). The addition of G-CSF in 1994 was associated with more rapid neutrophil engraftment: 11 days with G-CSF vs 18 days without growth factor (Wilcoxon, P Ͻ 0.0001). Patients reached and maintained a platelet count of 20 ϫ 10 9 /l at a median of 17 days (range 7-37 days). G-CSF administration did not significantly influence platelet recovery with medians of 15 vs 19 days for patients with and without G-CSF, respectively (Wilcoxon, P = 0.38).
Toxicity
Five patients (23%) developed grades 2-4 acute GVHD (four grade 2, one grade 3). Three patients went on to develop chronic GVHD confined to the skin requiring ongoing systemic immune suppressive medication. There was only one death secondary to transplant-related toxicity -interstitial pneumonitis in a patient with GVHD 6 months post BMT (Figure 1 ). Regimen-related toxicities were otherwise rare. One patient developed significant hemorrhagic cystitis. One patient developed a secondary EBV-related lymphohoproliferative process 4 months post BMT. The process resolved completely with interferon, acyclovir and immune globulin therapy. He remains disease free 29 months post BMT. No patients required mechanical ventilation for respiratory failure and none have required hemodialysis. There have been no cases of hepatic venoocclusive disease. All surviving patients are clinically well and have Karnofsky performance scores of 90% or greater.
Disease relapse and survival
The primary cause of treatment failure in this cohort of patients was disease relapse. Eight patients experienced disease recurrence at a median of 6.5 months (range 2-26 months) after BMT. Three of these relapses occurred in patients who had failed a prior autologous transplant. Overall, 13 of 22 patients remain alive, free of disease at a median follow-up of 32 months. Event-free survival ( Figure  2a ) is estimated at 54% (90% CI, 38-72%) at 30 months post transplant, and overall survival is estimated at 59% at 40 months for the entire group (Figure 2b) . Among the patients undergoing marrow transplantation for the first time, EFS is estimated at 64% at 30 months.
Patient characteristics were investigated as potentially prognostic of improved EFS or OS. These included remission status at BMT (CR or PR), development of GVHD (in allogeneic patients only), number of prior regimens (one, two, or three or more), T cell or B cell disease, previous autologous transplant, dose of TBI, and histologic grade (low, intermediate or high). Univariate comparisons did not identify any factor which was statistically significant at the 0.05 level (data not shown). 
Discussion
Our encouraging experience with allogeneic BMT using CD6 + T cell depletion as GVHD prophylaxis raises the question of whether patients and their families should be tested for HLA identity when marrow or stem cell transplantation is being contemplated. The resistance to such an approach would naturally come from fear of excessive undue toxicity associated with allogeneic BMT as well as the knowledge that autologous transplantation has produced a significant number of long-term remissions in selected patients. Only if allogeneic transplantation could be performed with a minimum of morbidity and mortality and if the use of allogeneic marrow could lower the risk of relapse in certain patient subgroups would searching for a family donor be appropriate.
Several single institution studies have attempted to compare results of allogeneic and autologous marrow transplantation for NHL in an attempt to determine if indeed a graftversus-lymphoma effect could be demonstrated. These studies, have, by and large, been retrospective analyses of somewhat heterogeneous patient populations. In most series, patients received traditional chemoprophylaxis to prevent GVHD rather than T cell depletion. Jones et al 7 reported a lower relapse rate after allo-BMT than after auto-BMT. However, disease-free survival was similar because of a 42% non-relapse mortality in allogeneic marrow recipients with chemosensitive disease. A case controlled analysis of allogeneic vs autologous transplantation in 101 patients using data from the EBMTR was conducted and revealed a somewhat lower risk of relapse after allogeneic transplantation compared to auto-BMT (23 vs 38%). 8 However, again, disease-free survival was similar (49 vs 46%) due to higher toxicity in the allo-transplant group. In this study, a correlation between the development of chronic GVHD and protection from relapse was identified, supporting the notion of a graft-versus-lymphoma effect. A prospective study of allogeneic vs autologous transplantation also resulted in lower rates of relapse after allo-BMT compared to autologous transplant.
9 Although no effect of acute GVHD on relapse was noted, the development of chronic GVHD appeared to be associated with improved progression-free survival.
If a graft-versus-lymphoma effect exists, will it be abrogated by T cell depletion? T cell depletion has been associated with an increased risk of relapse in patients transplanted for chronic myelogenous leukemia (CML). 19, 20 The effect of T cell depletion on relapse of other leukemias is less clear. 21 Our own experience suggests favorable results with CD6 depletion of donor marrow for patients with acute leukemia transplanted in first remission. 13 The effect of CD6 depletion on graft-versus-lymphoma activity remains uncertain. It is difficult to interpret the significance of the eight relapses we observed in the 22 patients we have reported. The incidence of relapse appears somewhat lower than that reported in many series on autologous transplantation for NHL (50-60%) but more patients are needed to more accurately ascertain the relapse rate after CD6-depleted allo-BMT. If, indeed, some degree of graft-versuslymphoma activity is lost by donor marrow T cell depletion, it may be possible to restore some of this activity by post-transplant immunomodulatory strategies, such as infusion of defined numbers of T cells or T cell subsets or by the administration of agents such as interleukin-2. [22] [23] [24] [25] Are there specific disease subgroups for which allogeneic transplantation would be preferable to autologous transplantation? A recent preliminary report with limited followup on allogeneic BMT in a small number of patients with follicular lymphoma suggested that this approach might be superior to autologous transplantation for this disease. 26 Clearly, more patients with longer follow-up are necessary to evaluate the role of allo-BMT for low-grade lymphoma. Nonetheless, the potential use of allogeneic transplantation for follicular lymphoma is intriguing given that there is a high frequency of lymphomatous involvement of the marrow in this disease and that the inability to purge harvested autologous bone marrow of bcl-2 lymphoma cells has been associated with a high likelihood of disease recurrence after auto-BMT. 27 While results of autologous transplantation for high-grade lymphoma have been reasonably encouraging for certain patients transplanted in first remission, auto-BMT outcomes for patients with recurrent disease following chemotherapy have been less promising and invite trials of allogeneic transplantation in this setting. 28 The low incidence of transplant-related complications associated with CD6 depletion of donor marrow makes it an alternative worthy of consideration when contemplating performing an autologous transplant for NHL. Engraftment in the presence of G-CSF is rapid after CD6 depletion, similar to that reported after autologous peripheral blood stem cell infusions. Moreover, there does not appear to be a risk of developing myelodysplasia or secondary leukemia after allo-BMT as has been reported recently following autologous BMT. Transplant-related mortality is clearly lower with CD6 depletion than that reported in most allogeneic transplant series and is comparable with many auto-BMT reports. Allogeneic BMT incorporating CD6 depletion of donor marrow or other GVHD prophylaxis methods yielding similar results should be prospectively compared to autologous transplantation for specific subgroups of patients with recurrent NHL.
